ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will participate in the 36th Annual J.P. Morgan Healthcare Conference on January 10, 2018, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s presentation will begin at 4 p.m. PST and …

The EF-14 trial is the first trial in over a decade to demonstrate statistically and clinically significant extension of overall survival of patients with newly diagnosed glioblastoma regardless of patient characteristics ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the final analysis of its phase 3 pivotal trial of Optune in combination with …

PANOVA 3 will determine the efficacy and safety of Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine as a frontline treatment for unresectable locally advanced pancreatic cancer Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine more than doubled progression free survival and the one-year survival rate compared to historical controls in Novocure’s phase …

Japan represents the largest medical device market in which Novocure has received governmental reimbursement for Optune for the treatment of newly diagnosed glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the Japanese Ministry of Health, Labour and Welfare has approved the recommendation by Japan’s Central Social Insurance Medical Council (Chuikyo) to provide reimbursement …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences in December. Asaf Danziger, Novocure’s Chief Executive Officer, and Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in a fireside chat at the Nasdaq 37th International Investor Conference on December 5, 2017, in London. Mr. Danziger and Mr. …

Increased compliance with Optune predicted survival in Novocure’s phase 3 pivotal EF-14 trial in newly diagnosed glioblastoma An Optune compliance threshold as low as 50 percent correlated with significantly improved outcomes in patients treated with Optune together with temozolomide versus patients treated with temozolomide alone ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today results from …

In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today 28 presentations on Tumor Treating Fields from externally led clinical research and analysis at …

Simulation research supports commitment to advance engineering of Tumor Treating Fields delivery systems In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today 10 presentations on …

An oral presentation will focus on the induction of autophagy by Tumor Treating Fields In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today …